Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 1;14(3):360-373.
doi: 10.21037/hbsn-24-58. Epub 2024 Aug 2.

Intention-to-treat approach for survival benefit of ABO-incompatible living-donor liver transplantation in patients with high Model for End-stage Liver Disease scores

Seung Hyuk Yim  1 , Deok-Gie Kim #  2 , Minyu Kang  2 , Hwa-Hee Koh  2 , Mun Chae Choi  2 , Eun-Ki Min  2 , Jae Geun Lee  2 , Myoung Soo Kim  2 , Dong Jin Joo #  2
Affiliations

Intention-to-treat approach for survival benefit of ABO-incompatible living-donor liver transplantation in patients with high Model for End-stage Liver Disease scores

Seung Hyuk Yim et al. Hepatobiliary Surg Nutr. .

Abstract

Background: ABO-incompatible (ABOi) living-donor liver transplantation (LDLT) is increasingly considered for patients with end-stage liver disease or hepatocellular carcinoma, in regions facing severe organ shortage. However, its applicability for patients with high Model for End-stage Liver Disease (MELD) scores remains uncertain. We aimed to investigate the survival benefit of ABOi-LDLT in high MELD patients using intention-to-treat (ITT) analysis in retrospective cohort study.

Methods: In a single-center study, 649 patients on a liver transplantation (LT) waitlist were divided into three groups: ITT-ABOi-LDLT (n=45), ITT-ABO-compatible (ABOc)-LDLT (n=162), and ITT-deceased-donor LT (DDLT) (n=442).

Results: The ITT-ABOi-LDLT group had a median initial isoagglutinin-titer of 1:128 and 71.1% underwent ABOi-LDLT after desensitization. This group showed a higher survival rate compared to ITT-DDLT (66.7% vs. 28.7%, P<0.001), and ABOi-LDLT intention was linked to significantly lower mortality (hazard ratio, 0.32; P<0.001). Survival among LT recipients was similar across ABOi-LDLT, DDLT, and ABOc-LDLT (P=0.13), but ABOi-LDLT recipients had higher biliary stricture rates compared to DDLT (25% vs. 10%, P=0.04). Donor postoperative outcomes were comparable between ABOi- and ABOc-LDLT. Higher initial isoagglutinin-titers in ABOi-LDLT recipients were associated with increased in-hospital mortality and graft loss but not with antibody-mediated rejection or isoagglutinin-titer rebound.

Conclusions: ABOi-LDLT offers a viable option for high MELD score patients, improving survival compared to DDLT and yielding similar posttransplant outcomes to DDLT and ABOc-LDLT in severe organ shortage region.

Keywords: ABO-incompatible transplantation (ABOi transplantation); end-stage liver disease; living-donor liver transplantation (LDLT); organ shortage; waitlist mortality.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-24-58/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of study. LT, liver transplantation; MELD, Model for End-stage Liver Disease; HCC, hepatocellular carcinoma; ITT, intention-to-treat; ABOi, ABO-incompatible; LDLT, living-donor liver transplantation; ABOc, ABO-compatible; DDLT, deceased-donor liver transplantation.
Figure 2
Figure 2
Survival after being waitlisted with a MELD score ≥30, according to treatment intention. ITT, intention-to-treat; ABOi, ABO-incompatible; LDLT, living-donor liver transplantation; ABOc, ABO-compatible; DDLT, deceased-donor liver transplantation; MELD, Model for End-stage Liver Disease.
Figure 3
Figure 3
Post-transplant survival after ABOi-LDLT and ABOc-LDLT. †, ABOi-LDLT vs. DDLT; ‡, ABOi-LDLT vs. ABOc-LDLT. ABOi, ABO-incompatible; LDLT, living-donor liver transplantation; ABOc, ABO-compatible; DDLT, deceased-donor liver transplantation; LT, liver transplantation.
See this image and copyright information in PMC

References

    1. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant 2015;15:17-38. 10.1111/ajt.12907 - DOI - PubMed
    1. Goldaracena N, Barbas AS. Living donor liver transplantation. Curr Opin Organ Transplant 2019;24:131-7. 10.1097/MOT.0000000000000610 - DOI - PubMed
    1. Yoshizumi T, Taketomi A, Soejima Y, et al. Impact of donor age and recipient status on left-lobe graft for living donor adult liver transplantation. Transpl Int 2008;21:81-8. - PubMed
    1. Yi NJ, Suh KS, Lee HW, et al. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. Liver Transpl 2009;15:496-503. 10.1002/lt.21606 - DOI - PubMed
    1. Liu CL, Lam B, Lo CM, et al. Impact of right-lobe live donor liver transplantation on patients waiting for liver transplantation. Liver Transpl 2003;9:863-9. 10.1053/jlts.2003.50163 - DOI - PubMed

LinkOut - more resources